If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Dulaglutide is a human glucagon-like peptide-1 receptor agonist that delays gastric emptying. The delay is longest after the first dose and diminishes with subsequent doses. Because dulaglutide slows gastric emptying, it may reduce the extent and rate of absorption of orally coadministered medications (Trulicity Package Insert, 2017).
In clinical pharmacology studies, dulaglutide did not affect the absorption of the tested, orally administered medications (lisinopril, metoprolol, digoxin, norelgestromin, ethinylestradiol, atorvastatin, metformin, acetaminophen, S-warfarin, R-warfarin, sitagliptin) to any clinically relevant degree. No dose adjustment is recommended for any of these coadministered medications (Trulicity Package Insert, 2017).
Caution should be exercised when oral medications are concomitantly administered with dulaglutide. Drug levels of oral medications with a narrow therapeutic index should be adequately monitored when concomitantly administered with dulaglutide (Trulicity Package Insert, 2017).
Dulaglutide has not been studied in patients with severe gastrointestinal disease, including severe
Enclosed Prescribing Information
Trulicity [package insert]. Indianapolis, IN: Eli Lilly and Company; 2017.
Date of Last Review: January 15, 2018